HTG Molecular Diagnostics Inc (STU:65H)
€ 0.242 0 (0%) Market Cap: - Enterprise Value: - PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

HTG Molecular Diagnostics Inc Host a Key Opinion Leader (KOL) Webinar Transcript

Jul 27, 2022 / 02:00PM GMT
Release Date Price: €14.05 (-7.65%)
Unidentified Company Representative

Good morning, and welcome to the HTG Molecular KOL webinar. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the HTG Molecular website following the conclusion of the event.

I'd now like to turn the call over to John Lubniewski, President and Chief Executive Officer of HTG Molecular. Please go ahead, John.

John L. Lubniewski
HTG Molecular Diagnostics, Inc. - President, CEO & Director

Yes. Thank you, and I'd like to welcome all of our attendees this morning. I think we've got a really interesting program. We're going to talk about what we see as a very disruptive and exciting new way to develop new lead candidates for pharmaceuticals.

And with us today, we've got an outstanding cast of speakers, most notably, Dr. Robert Spitale from UC Irvine as well as some internal speakers from HTG. So without further ado, I'd like to introduce Dr. Steve Barat. Steve runs our pharma programs. He joined us from Johnson and Janssen, where he was the U.S. Head of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot